Highest-materiality recent filing
Effective May 1, 2026, Lori Firmani will cease serving as CFO of Damora Therapeutics.
Damora Therapeutics dismisses EY Denmark auditor, appoints EY US
Audit Committee dismissed EY Denmark on April 17, 2026; EY US appointed same day.
Damora Therapeutics appoints Jennifer Jarrett as CEO, adds two directors, names chairman
Jennifer Jarrett appointed President and CEO, effective March 30, 2026; also joins board.
Galecto rebrands as Damora Therapeutics (DMRA); $535M cash; DMR-001 IND mid-2026
Name changed from Galecto to Damora Therapeutics; trades on Nasdaq as DMRA from March 10, 2026.
Galecto raises $295.9M in equity offering; funds Phase 3 of DMR-001
Offering of 14,473,685 shares at $19.00 each; underwriters' option for 2,171,052 additional shares exercised in full.
CEO Hans T. Schambye departs effective Feb 10, 2026; COO Sherwin Sattarzadeh appointed interim principal executive officer.
Filed under Item 7.01 with a corporate presentation (January 2026) as Exhibit 99.1.
Galecto appoints Sherwin Sattarzadeh as COO; issues warrant to Paramora
Sherwin Sattarzadeh appointed COO effective Jan 5, 2026; base salary $540,000, target bonus 40%.
Galecto corrects Series C Preferred Stock authorization from 43,855 to 43,882 shares
Filed Certificate of Correction on Dec 5, 2025 to fix inadvertent error in Series C Preferred Stock designation.
Galecto acquires Damora, raises ~$285M PIPE, appoints Fairmount-affiliated directors
Galecto acquired Damora Therapeutics; issued 265,309 common shares, 16,366 Series B and 4,241 Series C preferred shares to Damora stockholders.
Carl Goldfischer and David Shapiro elected as Class II directors with 219,253 and 226,360 votes for; 435,515 broker non-votes.
Galecto appoints Dr. Amy Wechsler to Board of Directors effective October 11, 2024
Board expanded to seven members; Wechsler appointed as Class I director with term through 2027 annual meeting.
Galecto acquires global rights to BRM-1420 dual ENL-YEATS/FLT3 inhibitor for AML
Galecto issued 62,594 common shares and 160.562 Series A convertible preferred shares (convertible into 160,562 common) to Bridge Medicines.
Galecto regains Nasdaq minimum bid price compliance; matter closed
Received Nasdaq Staff letter confirming compliance with Rule 5550(a)(2) based on bid price >= $1.00 from Aug 30 to Sep 13, 2024.
Galecto completes 1-for-25 reverse stock split; post-split shares at 1,248,266
Reverse stock split effective August 29, 2024; every 25 shares converted to 1 share.
Galecto effectuates 1-for-25 reverse stock split effective August 29, 2024
Stockholders approved reverse split at June 20 special meeting; board set ratio at 1-for-25.
Galecto shareholders approve reverse stock split and elect Anne Prener to board
Director Anne Prener elected with 10,651,770 for, 711,618 withheld; 5,840,793 broker non-votes.
Galecto transfers to Nasdaq Capital Market; granted 180-day extension for bid price compliance
Transferred listing from Nasdaq Global Select to Nasdaq Capital Market effective March 22, 2024.
the Board appointed Brian Burkavage, the Company’s current Senior Vice President, Finance, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Time.
the Board of Directors (the “Board”) of Damora Therapeutics, Inc. (the “Company”) determined that, effective as of May 1, 2026 (the “Effective Time”), Lori Firmani would cease serving as the Company’s Chief Financial Officer.
appointed Amy Wechsler to join the Board, effective as of October 11, 2024.
Max materiality 0.90 · Median 0.57 · Most common event other_material